Fig. 2: Survival times in the RASwt population that were per protocol accessible for tumour response (n = 352).
Progression-free (a) and overall (b) survival in the RAS wild-type per-protocol population (N = 352). Bev bevacizumab, Cet cetuximab.
Fig. 2: Survival times in the RASwt population that were per protocol accessible for tumour response (n = 352). | British Journal of Cancer
